LobbyingCancercare lobbying by quarter
Cancercare's latest lobbying report covers Q2 2026, at $15K. The four quarters Q4 2025–Q3 2026 total $45K. Its first report covers Q3 2025; the issues it reports most are Insurance.
Cancercare
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $45K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q3 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2025 | $0 | 1 |
| Q4 2025 | $15K | 1 |
| Q1 2026 | $15K | 1 |
| Q2 2026 | $15K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Insurance$45K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
Firms it paid
| Firm | ||
|---|---|---|
| Patterson & Meek | $45K | 4 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/16for Q2 | Patterson & Meek | $15K |
| 05/05for Q1 | Patterson & Meek | $15K |
| 01/20for Q4 2025 | Patterson & Meek | $15K |
| 25/10/28for Q3 2025 | Patterson & Meek | Under $5,000 |
| 25/07/24for Q3 2025 | Patterson & Meek | Under $5,000 |